Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting

Journal Francais d'Ophtalmologie

Volumn 38, Issue 7, 2015, Pages 620-627

  Boulanger Scemama, E ^a   Querques, G ^a   About, F ^a,b   Puche, N ^a   Srour, M ^a   Mane, V ^a   Massamba, N ^a   Canoui Poitrine, F ^a,b   Souied, E H ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

Anti vascular endothelial growth factor; Exudative age related macular degeneration; Long term follow up; Ranibizumab

Indexed keywords

ANGIOGENESIS INHIBITOR; RANIBIZUMAB; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; AMBULATORY CARE; ANTAGONISTS AND INHIBITORS; ECONOMICS; FEMALE; FOLLOW UP; FRANCE; HEALTH CARE DELIVERY; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MOTIVATION; PATIENT COMPLIANCE; PSYCHOLOGY; QUESTIONNAIRE; RETROSPECTIVE STUDY; SOCIAL ISOLATION; STATISTICS AND NUMERICAL DATA; TRAVEL; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; FEMALE; FOLLOW-UP STUDIES; FRANCE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTRAVITREAL INJECTIONS; LOST TO FOLLOW-UP; MALE; MIDDLE AGED; MOTIVATION; OFFICE VISITS; PATIENT COMPLIANCE; RANIBIZUMAB; RETROSPECTIVE STUDIES; SOCIAL ISOLATION; SURVEYS AND QUESTIONNAIRES; TRAVEL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84941600923     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfo.2014.11.015     Document Type: Article

References (17)

1. N.M. Bressler Age-related macular degeneration is the leading cause of blindness JAMA J Am Med Assoc 291 2004 1900 1901
2. R. Velez-Montoya, S.C.N. Oliver, J.L. Olson, S.L. Fine, H. Quiroz-Mercado, and N. Mandava Current knowledge and trends in age-related macular degeneration: genetics, epidemiology, and prevention Retina Phila Pa 34 2014 423 441
3. P.J. Rosenfeld, D.M. Brown, J.S. Heier, D.S. Boyer, P.K. Kaiser, C.Y. Chung, and et al. Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
4. D.M. Brown, P.K. Kaiser, M. Michels, G. Soubrane, J.S. Heier, R.Y. Kim, and et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
5. P. Abraham, H. Yue, and L. Wilson Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2 Am J Ophthalmol 150 2010 315e1 324e1
6. G.A. Lalwani, P.J. Rosenfeld, A.E. Fung, S.R. Dubovy, S. Michels, W. Feuer, and et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am J Ophthalmol 148 2009 43e1 58e1
7. G. Querques, S. Azrya, D. Martinelli, E. Berboucha, A. Feldman, A. Pece, and et al. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting Br J Ophthalmol 94 2010 292 296
8. H. Oubraham, S.Y. Cohen, S. Samimi, D. Marotte, I. Bouzaher, P. Bonicel, and et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration Retina Phila Pa 31 2011 26 30
9. S.Y. Cohen, L. Dubois, R. Tadayoni, F. Fajnkuchen, S. Nghiem-Buffet, C. Delahaye-Mazza, and et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting Am J Ophthalmol 148 2009 409 413
10. A. Oishi, M. Mandai, A. Nishida, M. Hata, T. Matsuki, and Y. Kurimoto Remission and dropout rate of anti-VEGF therapy for age-related macular degeneration Eur J Ophthalmol 21 2011 777 782
11. K.M. Droege, P.S. Muether, M.M. Hermann, A. Caramoy, U. Viebahn, B. Kirchhof, and et al. Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life Graefes Arch Clin Exp Ophthalmol 251 2013 1281 1284
12. S. Pushpoth, E. Sykakis, K. Merchant, A.C. Browning, R. Gupta, and S.J. Talks Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration Br J Ophthalmol 96 2012 1469 1473
13. A. Rasmussen, S.B. Bloch, J. Fuchs, L.H. Hansen, M. Larsen, M. Lacour, and et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration Ophthalmology 120 2013 2630 2636
14. M. Krüger Falk, H. Kemp, and T.L. Sørensen Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment Am J Ophthalmol 155 2013 89e3 95e3
15. K.M. Droege, A. Caramoy, A. Kersten, J. Luberichs-Fauser, K. Zilkens, D. Müller, and et al. Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration - monthly injections versus pro re nata Graefes Arch Clin Exp Ophthalmol 252 2014 31 34
16. J.S. Heier, D.M. Brown, V. Chong, J.-F. Korobelnik, P.K. Kaiser, Q.D. Nguyen, and et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548
17. U. Schmidt-Erfurth, P.K. Kaiser, J.-F. Korobelnik, D.M. Brown, V. Chong, Q.D. Nguyen, and et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies Ophthalmology 121 2014 193 201